Welcome reception

Meeting objectives & introduction
Naval Daver & Andrew Wei

Session 1: New research perspectives in AML
Chairs: Ravi Majeti & Iannis Aifantis

• Clonal Evolution in AML: Ravi Majeti
• Predictors of transformation in CHIP and CCUS and ways to optimize prediction: Koichi Takahashi
• Potential for early intervention in CHIP and CCUS: Uma Borate

Panel discussion

• Familial leukemia predispositions: understanding, identifying, and monitoring: Courtney DiNardo
• Harnessing epigenetic information in AML to identify novel potential therapeutic approaches: Maria “Ken” Figueroa
• Deconvoluting clonal and cellular architecture in IDH-mutant AML: Iannis Aifantis
• Ancestry-inclusive consideration of AML genomics: Ann-Kathrin Eisfeld

Panel discussion

Break

Session 2: Controversies in AML
Chairs: Gail Roboz & Naval Daver

• Improving intensive chemotherapy approaches in frontline AML: Tapan Kadia
• Which patients should have allogeneic transplants in 2023?: Charles Craddock
• Intensive chemo or HMA + VEN intermediate for younger AML patients?: Eunice Wang
• Keeping AML patients in remission – maintenance vs transplant: Gail Roboz

Panel discussion

• Optimizing therapy in secondary AML and optimal use of CPX-351: Tara Lin
• Clinical approaches for IDH-mutated AML: Eytan Stein
• Frontline approaches for FLT3-mutant AML: Harry Erba
• Current approaches for relapsed FLT3-mutant AML: Jessica Altman

Panel discussion

Session 3: New frontiers in MRD for AML clinical practice
Chairs: Richard Stone & Marina Konopleva

• Single-cell sequencing and clinical applicability in detection and therapy of AML: Catherine Smith
• Value of MRD assessment in non-intensive regimens in AML: Farhad Ravandi-Kashani
• Value of MRD assessment in intensive regimens in AML: Maximillian Stahl
• MRD as a clinical endpoint in clinical trials: Roland Walter
• Applying MRD techniques in FLT3 mutated AML – are we able to use MRD as an endpoint in FLT3 AML?: Alexander Perl
• MRD-directed interventions: Andrew Wei

Panel discussion

Lunch

Session 4: BPDCN & MDS/MPN + CMML
Chairs: Naveen Pemmaraju & Mrinal Patnaik

• Updates in diagnosis, pathogenesis and future directions in BPDCN: Naveen Pemmaraju
• Current and new directions for accelerated/BP/transformed MPN: Anand Patel
• VEXAS: a new entity: Emma Groarke
• Future targets and drug development in CMML: Mrinal Patnaik
• Bench to bedside in MPNs: CALR and targeting CALR: Naveen Pemmaraju
• Novel targeted Agents in MPNs: Raajit Rampal

Panel discussion

Break

Session 5: Novel targets, combinations and treatments in AML
Part 1 – new AML therapies and limitations
Chairs: Andrew Wei and Eunice Wang

Keynote talk
History of development and future directions for FLT3 inhibitors in AML: Mark Levis

New AML therapies and limitations

• Optimizing doublet and triplet combinations in AML – improving efficacy while maintaining safety: Naval Daver
• Uproleselan in frontline and R/R AML: Geoffrey Uy
• TP53 treatment strategies in AML: Thomas Cluzeau

Panel discussion

• Menin inhibitors in AML: Ghayas Issa
• Mechanisms of resistance and combination approaches with menin inhibitors in AML: Eytan Stein
• Targeting resistance to venetoclax-based therapies: Marina Konopleva
• Resistance to FLT3 inhibitors: Catherine Smith

Panel discussion

Day 1 ends

Introduction to Day 2
Naval Daver & Andrew Wei

Session 6: Special session on regulatory endpoints in AML
Chairs: Courtney DiNardo & Mark Levis

• The FDA’s perspective on regulatory endpoints in AML: Joseph Wynne
• A clinical investigator’s perspective on endpoints and drug development in AML: Naval Daver

Panel discussion including Kelly Norsworthy

Session 7: Novel targets, combinations, and treatments in AML
Part 2 – what do we know about drug resistance?
Chairs: Charles Craddock & Courtney DiNardo

• Genomic landscape and prognostic implications of TP53 mutations in AML: Sanam Loghavi
• p53 reactivators and magrolimab in TP53-mutant MDS/AML: David Sallman
• Novel pro-survival combinations: Andrew Wei

Break

Session 8: Transplant and immunotherapies in AML
Chairs: Charles Craddock & David Sallman

• Vedolizumab for prophylaxis and treatment of acute GvHD post-alloSCT: Yngvar Fløisand
• Updates in the use of post-transplant cyclophosphamide: Nelli Bejanyan
• Which patients with AML in MRD+ CRi should be transplanted?:Roland Walter
• Lessons from the MORPHO trial: Mark Levis
• Novel T-cell approaches for R/R AML (excluding CAR-T): Nelli Bejanyan
• Early phase CAR-T and NK cell trials for R/R AML and MDS: David Sallman

Panel discussion

Meeting conclusions & final remarks